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 INTRODUCTION
 Non-alcoholic fatty liver disease (NAFLD) is the most com-
mon liver disease in many developed countries and now aff ects 
20–30% of the population, although many aff ected individuals go 
unrecognized ( 1–4 ). NAFLD has a variable prognosis, with the 
majority of patients having benign disease without associated 
liver-related morbidity or mortality ( 5 ). However, approximately 
40% of patients with NAFLD develop progressive fi brosis that can 
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 OBJECTIVES:  Non-invasive fi brosis scores are widely used to identify/exclude advanced fi brosis in patients with 
non-alcoholic fatty liver disease (NAFLD). However, these scores were principally developed and 
validated in patients aged between 35 and 65 years of age. The objective of this study was to assess 
the effect of age on the performance of non-invasive fi brosis tests in NAFLD.
 METHODS:  Patients were recruited from European specialist hepatology clinics. The cohort was divided into fi ve 
age-based groups: ≤35 ( n =74), 36–45 ( n =96), 46–55 ( n =197), 56–64 ( n =191), and ≥65 years 
( n =76), and the performance of the aspartate aminotransferase (AST)/alanine transaminase (ALT) 
ratio, fi brosis 4 (FIB-4), and NAFLD fi brosis score (NFS) for advanced fi brosis (stage F3–F4) for each 
group was assessed using liver biopsy as the standard.
 RESULTS:  Six hundred and thirty-four patients were included. The diagnostic accuracy of the AST/ALT ratio 
was lower than NFS and FIB-4 in all the age groups. The AST/ALT ratio, NFS, and FIB-4 score 
performed poorly for a diagnosis of advanced fi brosis in those aged ≤35 years (area under the 
receiver operating characteristic curves (AUROCs 0.52, 0.52, and 0.60, respectively). For all groups 
>35 years, AUROCs for advanced fi brosis were similar for the NFS and FIB-4 score (range 0.77–
0.84). However, the specifi city for advanced fi brosis using the FIB-4 and NFS declined with age, 
becoming unacceptably low in those aged ≥65 years (35% for FIB-4 and 20% for NFS). New cutoffs 
were derived (and validated) for those aged ≥65 years, which improved specifi city to 70% without 
adversely affecting sensitivity (FIB-4 2.0, sensitivity 77%; NFS 0.12, sensitivity 80%).
 CONCLUSIONS:  The NFS and FIB-4 scores have similar accuracy for advanced fi brosis in patients aged >35 years. 
However, the specifi city for advanced fi brosis is unacceptably low in patients aged ≥65 years, 
resulting in a high false positive rate. New thresholds for use in patients aged ≥65 years are 
proposed to address this issue.
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result in cirrhosis, putting patients at risk of hepatocellular car-
cinoma, liver failure, and portal hypertension-related complica-
tions ( 6–10 ). Th e development of advanced fi brosis (stage F3–F4) 
in patients with NAFLD is clinically important as it is associated 
with a more than threefold increased risk of mortality (all cause 
and liver related) compared with a reference population ( 11,12 ). 
It is therefore vital to identify patients with advanced fi brosis so 
that appropriate lifestyle interventions, treatment, or surveillance 
for complications can be initiated.
 Numerous non-invasive tests for liver fi brosis have been investi-
gated in patients with NAFLD, but to date, none have the accuracy 
to completely replace liver biopsy ( 13,14 ). Simple non-invasive 
fi brosis scores derived from routine clinical and biochemical 
indices, such as the aspartate aminotransferase (AST)/alanine 
transaminase (ALT) ratio, fi brosis 4 (FIB-4) score and NAFLD 
fi brosis score (NFS) have shown promise, particularly for exclud-
ing advanced fi brosis, and are therefore useful tools to risk stratify 
patients with NAFLD for further investigation ( 15–20 ). As a result, 
these non-invasive scores are now widely used “fi rst line” in pri-
mary and secondary care to assess fi brosis in patients with abnor-
mal liver enzymes and suspected NAFLD ( 21 ). Moreover, a recent 
Lancet Commission addressing liver disease has recommended 
that simple non-invasive scores be used to help identify patients 
with advanced fi brosis in the community ( 22 ).
 With the increasing use of simple non-invasive fi brosis mark-
ers to identify patients with advanced liver disease, it is impor-
tant to recognize and mitigate against any limitations of these 
tests. Th e majority of patients included in the studies on which 
these non-invasive scores were developed were aged between 35 
and 65 years, so there is potential for reduced effi  cacy of these 
tests in patients outwith this age distribution. Th e aim of this 
study was to assess whether age aff ects the diagnostic perfor-
mance of the AST/ALT ratio, FIB-4 score, and NFS for advanced 
fi brosis in a cohort of patients with biopsy-proven NAFLD. In 
particular, our aim was to assess the effi  cacy of these non-inva-
sive scores in younger (≤35 years) and older patients (≥65 years) 
with NAFLD and if necessary to derive specifi c cutoff s for use in 
those patients.
 METHODS
 Th is study included consecutive patients with biopsy-proven 
NAFLD who attended specialist fatty liver clinics at the Freeman 
Hospital, Newcastle upon Tyne, UK; Addenbrooke’s Hospital, 
Cambridge, UK; Antwerp University Hospital, Edegem, Belgium; 
and Pitié-Salpêtrière Hospital, Paris, France. Th ese formed the 
initial ascertainment cohort. Liver biopsies were conducted as per 
routine clinical care for the investigation of abnormal liver func-
tion tests (raised ALT, AST, or gamma-glutamyl transferase) or 
to stage disease severity in patients with radiological evidence of 
fatty liver. Clinical and laboratory data were collected prospec-
tively from the time of liver biopsy. Patients with evidence of other 
liver disease (autoimmune hepatitis, viral hepatitis, drug induced 
liver injury, hemochromatosis, cholestatic liver disease, or 
Wilson’s disease) were excluded. In addition, subjects consuming 
excessive amounts of alcohol (alcohol intake >20 g/day for 
women; >30 g/day for men) at the time of biopsy or in the past 
were excluded. Patients with incomplete data to calculate all the 
non-invasive scores were excluded.
 Relevant clinical details, including gender, age, weight, and 
height, were obtained at the time of biopsy. Th e body mass index 
was calculated by the formula: weight (kg)/height (m) 2 . Patients 
were identifi ed as having diabetes if they had been diagnosed 
with diabetes according to the 2004 American Diabetes Associa-
tion criteria or if they were taking an oral hypoglycemic drug or 
insulin ( 23 ).
 Percutaneous liver biopsies were performed as per unit proto-
col at the sites and were assessed by an experienced local hepato-
pathologist. Patients with liver biopsies specimens <15 mm in 
length were excluded. Histological scoring was performed accord-
ing to the non-alcoholic steatohepatitis (NASH) Clinical Research 
Network criteria ( 24 ). Th e NAFLD activity score was graded from 
0 to 8, including scores for steatosis (0–3), lobular infl ammation 
(0–3), and hepatocellular ballooning (0–2). NASH was defi ned as 
steatosis with hepatocyte ballooning and infl ammation ± fi brosis 
( 25 ). Fibrosis was staged from F0 to F4 ( 24 ). Patients with stage F3 
or F4 fi brosis were considered to have advanced fi brosis.
 Th e AST/ALT ratio, FIB-4, and NFS were calculated from blood 
tests taken at the time of liver biopsy as previously described 
( 16,26,27 ). Details of the formulas and cutoff s for the tests under 
investigation are shown in  Table 1 . Previously published cutoff s 
were used to exclude and diagnose advanced fi brosis for each score 
( 15,16,18,19 )
 To validate new cutoff s for the NFS and FIB-4 score optimized 
for use in older patients (aged ≥65 years) that were derived 
in the initial ascertainment cohort, anonymized biochemical, 
histological, and anthropometric data were collected from a 
separate group of histologically characterized patients from the 
 Table 1 .  An overview of the simple non-invasive fi brosis markers 
under investigation ( 15,16,18,19,26,27 ) 
 Test  Calculation method  Lower cutoff  Upper cutoff 
 AST/ALT ratio  AST/ALT  0.8  1 
 FIB-4 score  Age×AST (IU/l)/platelet 
count (×10 9 /l)×√ALT 
(IU/l) 
 1.3  2.67 
 NAFLD fi brosis 
score (NFS) 
 −1.675+0.037×age 
(years)+0.094×BMI 
(kg/m 2 )+1.13×impaired 
fasting glycemia (IFG) 
or diabetes (yes=1, 
no=0)+0.99×AST/ALT 
ratio −0.013×platelet 
(×10 9 /l)−0.66×albumin 
(g/dl) 
 −1.455  0.676 
 ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body masss 
index; FIB-4, fi brosis 4; NAFLD, non-alcoholic fatty liver disease. A score below 
the lower cutoff is used to exclude advanced fi brosis (stage F3–F4) with reason-
able accuracy and a score above the upper cutoff is suggestive of the presence 
of advanced fi brosis in patients with NAFLD. 
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EPoS/EASL European NAFLD Registry. Th e “European NAFLD 
Registry” was established during the EU FP7 FLIP project (2010-) 
and is now maintained by the EU H2020 EPoS (Elucidating Path-
ways of Steatohepatitis) consortium to facilitate collaborative 
research into NAFLD. It is the largest multi-national registry of 
patients with histologically characterized NAFLD. Th ese patients 
had data collected according to the same methodology as the 
main cohort.
 All statistical analyses were performed using the SPSS soft ware 
version 22.0 (SPSS, Chicago, IL). Continuous normally distrib-
uted variables were represented as mean ± s.d. Categorical and 
non-normal variables were summarized as median and range. 
Chi squared tests were used to determine the distribution of cat-
egorical variables between groups. To compare the means of nor-
mally distri buted variables between groups, the Student’s  t -test or 
analysis of variance test was performed. To determine diff erences 
between groups for continuous non-normally distributed vari-
ables, medians were compared using the Mann–Whitney  U -test. 
Th e diagnostic performance of the non-invasive tests was assessed 
by receiver operating characteristic (ROC) curve analysis. Th e 
area under the ROC (AUROC) was used as an index to compare 
the accuracy of tests. Th e sensitivity, specifi city, positive predictive 
values (PPVs), negative predictive values (NPVs), positive likeli-
hood ratios (LR +ve), and negative likelihood ratios (LR −ve) for 
relevant cutoff s were also displayed. In order to assess changes in 
sensitivity and specifi city of the tests with age, plots of sensitivity 
and specifi city in diff erent age groups were displayed graphically. 
New cutoff s for the FIB-4 and NFS were derived for ≥65-year-
old patients by taking the point on the ROC where the combined 
value of sensitivity and specifi city was the highest. As the preva-
lence of advanced fi brosis can vary in diff erent populations, the 
PPVs and NPVs for the new cutoff s were displayed at advanced 
fi brosis prevalence rates of 5, 10, 20, 30, and 40%. A  P value of 
<0.05 was considered signifi cant.
 RESULTS
 Characteristics of the whole cohort
 A total of 634 patients with biopsy-proven NAFLD were included 
in the study, 369 from Newcastle, 138 from Antwerp, 99 from 
Paris, and 28 from Cambridge. Overall, 347 (55%) patients were 
male. Overall, the indication for liver biopsy was the assess-
ment of “raised” transaminases (serum ALT or AST >40 IU/ml) 
in 464 (73%) patients and for the staging of disease in 170 
(27%) patients with imaging evidence of steatosis and “normal” 
transaminase levels. Th e mean age was 51±12 years. Forty-three 
percent of the cohort were diabetic and the mean body mass index 
was 34.5 ± 6 kg/m 2 . In total, 461 (73%) patients had histological 
evidence of NASH and the median NAFLD activity score was 
4 ( 1–8 ). Overall, the median fi brosis stage was F1 (F0–F4); 164 
patients (25%) had advanced liver fi brosis (stage F3–F4).
 Effect of age on clinical factors in patients with NAFLD
 In order to assess the eff ect of age on clinical accuracy of simple 
non-invasive scores for NAFLD fi brosis, the cohort was stratifi ed 
by age into fi ve groups: ≤35, 36–45, 46–55, 56–64, and ≥65 years, 
respectively.  Table 2 displays the clinical, biochemical, and histo-
logical features of patients in each of these age groups. Overall, 
increasing age was signifi cantly associated with female gender 
( P <0.001) and the presence of Type 2 diabetes ( P <0.001) and 
NASH ( P =0.001), as well as increased fi brosis stage ( P <0.001), 
AST/ALT ratio ( P <0.001), NFS ( P <0.001), and FIB-4 score 
( P <0.001). In addition, there was a signifi cant negative association 
between age and platelet count ( P <0.001), serum ALT ( P <0.001), 
and serum albumin ( P <0.001)
 Diagnostic accuracy for advanced fi brosis using simple 
non-invasive fi brosis scores in patients by age group
 A detailed summary of the AUROC, sensitivity, specifi city, 
PPVs, NPVs, LR+ve, and LR-ve for the AST/ALT ratio, the FIB-4 
score, and the NFS is shown in  Table 3 for patients divided into 
the fi ve age groups. Overall, the performance of the AST/ALT 
ratio, NFS, and FIB-4 score was very poor in the ≤35-year-old 
patients (AUROCs 0.52, 0.52, and 0.60, respectively, all  P =NS), 
suggesting that these scores have insuffi  cient accuracy to have 
a role in the management of patients with NAFLD in this age 
group.
 Th e diagnostic accuracy of the AST/ALT ratio for advanced 
fi brosis was lower than the NFS and FIB-4 score across all age 
groups, with modest AUROCs ranging from 0.52 to 0.73. Th e 
NFS and FIB-4 score performed similarly well across all the age 
groups >35 years, with AUROCs for a diagnosis of advanced 
fi brosis ranging from 0.77 to 0.84. However, despite having 
similar AUROC for advanced fi brosis across age groups, the 
specifi city of the NFS and FIB-4 for advanced fi brosis fell with 
increasing age. Th is is illustrated in  Figure 1a–c , which shows 
plots of the sensitivity and specifi city against age for the AST/
ALT ratio, NFS, and FIB-4 score. Using the established diag-
nostic cutoff s for advanced fi brosis, the specifi city of the NFS 
and FIB-4 scores were very low in patients aged ≥65 years (20% 
at cutoff  −1.445 for NFS and 35% at cutoff  1.3 for FIB-4). Th is 
equates to an unacceptably high false positive rate for advanced 
fi brosis in patients aged >65 years. Th e observed decline in spec-
ifi city with increasing age is perhaps unsurprising as both the 
NFS and FIB-4 score incorporate age in the formula, but the fall 
in specifi city for advanced fi brosis with the AST/ALT ratio was 
unexpected.
 Effects of age on specifi city of AST/ALT ratio for advanced 
fi brosis
 Overall, there was a signifi cant negative association between age 
and serum ALT ( P <0.001), whereas there was no signifi cant rela-
tionship between age and AST. When the relationship between 
age and serum ALT in patients with no/mild fi brosis (stage 
F0–F1) or moderate-to-advanced fi brosis (stage F2–F4) were 
analyzed separately to correct for fi brosis, the signifi cant nega-
tive relationship between serum ALT and age persisted ( P <0.001 
for both see  Figure 2a,b ), suggesting the age-related fall in ALT 
level was independent of fi brosis stage. Th is relationship also per-
sisted when males and females were analyzed separately (data not 
The American Journal of GASTROENTEROLOGY    www.nature.com/ajg
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shown). No signifi cant relationship between serum AST level and 
age was observed ( Figure 2c,d ).
 Derivation of new cutoffs to exclude advanced fi brosis for the 
NFS and FIB-4 score in older patients (≥65 years)
 As NAFLD is highly prevalent in older patients, it would be par-
ticularly advantageous to have an accurate non-invasive test for 
fi brosis in this age group. In light of the poor specifi city of the 
NFS and FIB-4 scores for advanced fi brosis when the currently 
published diagnostic cutoff s are employed in patients aged ≥65 
years, our results imply that many patients with mild fi brosis will 
be wrongly classifi ed as having advanced fi brosis and so would 
undergo additional unnecessary investigations. To address this 
problem, optimized cutoff s were derived to improve specifi c-
ity and thus reduce the false positive rate. Adopting the revised 
threshold (FIB-4 >2.0) in patients aged ≥65 years, the sensitivity 
and specifi city attained for advanced fi brosis were 77% and 
70%, respectively. Similarly, the new age-adjusted NFS thresh-
old (NFS>0.12) yielded 80% sensitivity and 70% specifi city for 
advanced fi brosis. Plots showing the sensitivity and specifi city 
performance of these new thresholds across the age range are 
shown  Figure 3a,b . Application of the new cutoff  for the NFS 
in patients aged >65 years substantially reduced the number 
of patients with intermediate scores, so that the majority were 
defi nitively classifi ed as low risk or high risk and would not nec-
essarily need further investigation (percentage defi nitively cat-
egorized using the new cutoff  80% (61/76) vs. 45% (34/76) for 
the existing cutoff ). Th is was a substantial improvement over the 
performance of the existing cutoff  with slightly more cases cor-
rectly classifi ed (80% vs. 76%, respectively) with respect to their 
histological stage. For the FIB-4 score, the new cutoff  also defi ni-
tively classifi ed more patients as low risk or high risk than the 
existing cutoff  (82% (62/76) vs. 55% (42/76), respectively) while 
maintaining the correct classifi cation in 78% of cases. As PPVs 
and NPVs are a function of disease prevalence in the background 
population and the tests may be applied to populations where the 
prevalence of advanced fi brosis is lower than in our study cohort, 
the PPVs and NPVs for older patients (≥65 years) are displayed 
 Table 2 .  Effect of age on clinical, biochemical, and histological features in patients with NAFLD 
 Characteristics  ≤35 years,  n =74  36–45 years,  n =96  46–55 years,  n =197  56–64 years,  n =191  ≥65 years,  n =76  P  value 
 Age (years)  28±5  41±3  51±3  60±3  69±3  
 Gender (% of male)  72%  64%  57%  50%  32%  <0.001 a 
 BMI (kg/m 2 )  34.9±6.0  35.5±6.9  34.8±6.2  34±5.2  33.6±6.3  0.17 b 
 Diabetes  38%  38%  41%  53%  58%  <0.001 a 
 ALT (IU/l)  108±72  75±45  68±45  59±33  57±40  <0.001 b 
 AST (IU/l)  56±33  48±33  47±32  46±24  52±42  0.1 b 
 ALB (g/l)  46±7  45±4  45±5  44±4  45±5  <0.001 b 
 Platelets (×10 9 /l)  271±63  258±77  250±66  237±67  214±84  <0.001 b 
 AST/ALT ratio  0.58±0.18  0.68±0.29  0.74±0.28  0.83±0.34  1.01±0.45  <0.001 b 
 FIB-4 score  0.59±0.25  0.98±0.62  1.24±0.72  1.70±1.1  2.94±2.98  <0.001 b 
 NAFLD fi brosis score  −3.20±1.14  −2.03±1.52  −1.55±1.34  −0.88±1.36  0.08±1.54  <0.001 b 
 Fibrosis stage  0 (0–3)  0 (0–4)  1 (0.4)  2 (0–4)  2 (0–4)  <0.001 c 
 0  38 (51%)  50 (52%)  74 (37%)  50 (26%)  16 (21%)  
 1  20 (27%)  19 (20%)  48 (24%)  44 (23%)  17 (22%)  
 2  8 (11%)  9 (9%)  33 (17%)  33 (17%)  13 (17%)  
 3  8 (11%)  15 (16%)  33 (17%)  40 (21%)  15 (20%)  
 4  0 (0%)  3 (3%)  9 (5%)  24 (13%)  15 (20%)  
 Stage F3 or F4 fi brosis  8 (11%)  18 (19%)  42 (22%)  64 (34%)  30 (40%)  <0.001 a 
 NASH  45 (61%)  61 (64%)  141 (72%)  154 (81%)  60 (79%)  0.002 a 
 NAS  4 (1–7)  4 (1–7)  4 (1–8)  4 (1–8)  3 (1–7)  0.24 c 
 Raised transaminases  62 (84%)  74 (77%)  142 (72%)  137 (72%)  49 (64%)  0.083 a 
 ALB, albumin; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body masss index; FIB-4, fi brosis 4; NAFLD, non-alcoholic fatty liver disease; NAS, 
NAFLD Activity Score; NASH, non-alcoholic steatohepatitis. Data are expressed as mean±s.d. or median (range ). Raised transaminases=serum ALT or AST >40 IU/l. 
 a Chi-square test. 
 b Student’s  t -test. 
 c Mann–Whitney  U -test. 
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 Table 3 .  Performance of the tests for diagnosis/exclusion of advanced fi brosis by age group using established cutoffs ( 15,16,18,19 ) 
 Test  AUROC (95% CI)  Cutoff  Sens. (%)  Spec. (%)  PPV (%)  NPV (%)  LR +ve  LR −ve 
 ≤35 years 
 AST/ALT ratio  0.52 (0.29–0.75)  0.8  25  89  22  91  2.27  0.84 
   1  0  98.5  0  89  0  0.13 
 FIB-4 score  0.60 (0.40–0.81)  1.30  0  97  0  89  0  1.03 
   2.67  0  100  0  89  —  1 
   3.25  0  100  0  89  —  1 
 NFS  0.52 (0.32–0.73)  −1.455  0  91  0  88  —  1 
   0.676  0  100  0  89  —  1 
 36–45 years 
 AST/ALT ratio  0.66 (0.53–0.80)  0.8  39  80  31  85  1.95  0.76 
   1  6  94  19  81  1  1 
 FIB-4 score  0.79 (0.66–0.91)  1.30  56  91  59  90  6.2  0.48 
   2.67  17  100  100  84  ∞  0.83 
   3.25  6  100  100  82  ∞  0.94 
 NFS  0.86 (0.76–0.96)  −1.455  78  80  48  94  3.9  0.28 
   0.676  22  100  100  85  ∞  0.78 
 46–55 years 
 AST/ALT ratio  0.63 (0.53–0.73)  0.8  44  74  31  83  1.69  0.76 
   1  20  91  37  81  2.22  0.88 
 FIB-4 score  0.77 (0.68–0.86)  1.30  63  77  42  89  2.74  0.48 
   2.67  12  98.7  71  81  9.23  0.89 
   3.25  5  99.9  93  80  50  0.95 
 NFS  0.81 (0.73–0.89)  −1.455  81  65  38  93  2.31  0.29 
   0.676  22  97.4  69  82  8.46  0.8 
 56–64 years 
 AST/ALT ratio  0.72 (0.64–0.80)  0.8  64  69  52  79  2.06  0.52 
   1  38  92  71  74  4.75  0.67 
 FIB-4 score  0.84 (0.78–0.90)  1.30  90  61  54  92  2.3  0.16 
   2.67  30  97.6  86  73  12.5  0.72 
   3.25  20  100  100  71  ∞  0.8 
 NFS  0.83 (0.64–0.80)  −1.455  95  44  47  94  1.69  0.11 
   0.676  31  99.9  99  74  310  0.69 
 ≥65 years, n=76 
 AST/ALT ratio  0.73 (0.61–0.85)  0.8  80  48  50  79  1.53  0.42 
   1  67  76  64  78  2.79  0.43 
 FIB-4 score  0.81 (0.72–0.91)  1.30  93  35  48  89  1.43  0.2 
   2.67  53  85  69  74  3.53  0.55 
   3.25  50  91  78  74  5.55  0.55 
 NFS  0.81 (0.71–0.92)  −1.455  93  20  43  82  1.16  0.35 
   0.676  57  85  71  76  3.8  0.51 
 ALT, alanine transaminase; AST, aspartate aminotransferase; AUROC, area under the receiver operating characteristic curve; CI, confi dence interval; FIB-4, fi brosis 4; 
LR +ve, positive likelihood ratio, LR −ve, negative likelihood ratio; NFS, non-alcoholic fatty liver disease fi brosis score; NPV, negative predictive value; PPV, positive 
predictive value; Sens., sensitivity; Spec., specifi city. 
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across an advanced fi brosis prevalence scale in  Table 4 , which 
compares performance of the existing thresholds and our pro-
posed thresholds for the FIB-4 and NFS.
 Independent validation of new cutoffs for the NFS and FIB-4 
score in a separate patient cohort
 In order to validate the new cutoff s for the NFS and FIB-4 score 
in older patients, a second cohort of 61 patients with biopsy-
proven NAFLD aged ≥65-years but otherwise selected according 
to the same criteria as the fi rst cohort was assessed. Th e mean 
age of these patients was similar to the mean for the age in the 
≥65-years group in the ascertainment cohort at 69±3.4 years and 
41 (67%) were female. Overall 54 (89%) patients had NASH, 38 
(62%) were diabetic, and 24 (39%) had advanced fi brosis. Th e 
AUROC for a diagnosis of advanced fi brosis was 0.72 (95% con-
fi dence interval 0.59–0.85) for both the NFS and FIB-4 score. Th e 
sensitivity and specifi city for advanced fi brosis in these patients 
was similar to the main cohort (NFS: sensitivity 71% and speci-
fi city 68%; FIB-4 score: sensitivity 75% and specifi city 65%), con-
fi rming their validity.
 DISCUSSION
 Th e use of simple non-invasive fi brosis scores such as the NFS 
and FIB-4 score to identify or exclude advanced fi brosis as part of 
a staged approach to diagnosis and risk stratifi cation in patients 
with NAFLD is now widely adopted and recommended by most 
guidelines ( 1,2,13,28 ). Previous studies have shown that these 
scores can reliably exclude advanced fi brosis in patients with 
NAFLD, and as a result, they provide a useful, inexpensive fi rst-
line assessment of liver fi brosis for use in primary or secondary 
care ( 16,18,19 ). Although fi delity appears lower when applied in 
bariatric surgery cohorts ( 29 ), several studies have now validated 
their use in large populations of patients with biopsy-proven 
NAFLD ( 17,20,30–32 ). However, the majority of patients included 
in these studies were in middle age (typical mean age of 45–55 
years), with very few younger (≤35 years) or older patients (≥65 
years) included. With the widespread adoption of the FIB-4 and 
NFS, inevitably these tests are increasingly being used in patients 
outside the age range in which they have been validated. Anecdo-
tally, we have seen quite a number of older patients referred to our 
fatty liver clinics with intermediate or high NFS and FIB-4 scores 
who have no evidence of advanced fi brosis when assessed by other 
methods, such as elastography or biopsy. Th erefore, the aim of the 
present study was to assess the performance of these simple non-
invasive fi brosis scores in age-defi ned cohorts of patients of his-
tologically characterized NAFLD, with a particular focus on cases 
at the younger (<35 years) and older (≥65 years) ends of the age 
spectrum.
 One of the most notable fi ndings of this study was that, 
despite the FIB-4 and NFS having similar AUROCs in all age 
groups >35 years old, the specifi city for advanced fi brosis using 
the lower cutoff  with these tests fell sharply in the older patients 
and became unacceptably low in those aged ≥65 years (speci-
fi city 35% and 20%, respectively, for FIB-4 score and NFS). In 
essence, inclusion of age in the FIB-4 and NFS leads to a false 
infl ation of the score in patients aged >65 years, bringing more 
patients into the intermediate-risk bracket and increasing the 
high false positive rate. As a result, we have derived new lower 
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 Figure 1 .  Plots of sensitivity and specifi city against age for existing diag-
nostic cutoffs for advanced fi brosis for: ( a ) aspartate aminotransferase 
(AST)/alanine transaminase (ALT) ratio (0.8); ( b ) non-alcoholic fatty liver 
disease fi brosis score (NFS) (−1.445); ( c ) fi brosis 4 (FIB-4) score (1.3). 
These show a reduction in sensitivity and an increase in specifi city with 
age.
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a signifi cant age-related fall in serum ALT levels, which per-
sisted, independent of fi brosis stage and gender, and confi rms 
results of previous studies ( 33–35 ). As both the NFS and FIB-4 
score include a ratio of the AST and ALT in their models, this 
may well also contribute to the overall reduction in specifi c-
ity with increasing age. Serum ALT levels are well known to 
fall with increasing fi brosis stage, so one explanation for this 
observation may be that, with a higher prevalence of advanced 
fi brosis in older patients, the ALT fall in the older patients was 
due to increased fi brosis stage. However, re-analysis of the 
data stratifi ed by fi brosis stage demonstrates that this is not 
the explanation and so the underlying mechanism for the fall 
in ALT levels is not known. It is, however, consistent with the 
observation that many NAFLD patients have serum ALT lev-
els within the normal range, irrespective of disease activity. It 
once again highlights that clinicians should not rely on a raised 
serum ALT to support a diagnosis of NAFLD or as a marker of 
disease severity, particularly in older individuals. It also raises 
the broader question of whether age-specifi c normal ranges for 
serum ALT should be defi ned. Th erefore, the likely explanation 
for the reduced specifi city of the AST/ALT ratio for advanced 
fi brosis is that, even in the absence of liver disease, there is a 
natural age-related fall in serum ALT level (while the AST level 
remains stable). Th is increases the AST/ALT ratio and, as a 
result, reduces the specifi city of this test for advanced fi bro-
sis. In addition to the eff ect of age on transaminase levels, we 
found a negative association between age and platelet count, 
confi rming previous epidemiological studies ( 36 ). Both NFS 
cutoff s for the FIB-4 score and NFS for use in patients aged ≥65 
years, which reduced the number of patients with an indeter-
minate score. Use of these thresholds in patients aged ≥65 years 
increased the specifi city for advanced fi brosis using the NFS and 
FIB-4 score to 70%, eff ectively controlling the false positive rate 
without adversely infl ating the false negative rate of the test. Th e 
upper cutoff s remained the same. Th e advantage of adopting 
these cutoff s was confi rmed in a separate validation cohort. We 
believe that introduction of these new cutoff s for older patients 
will have a direct benefi t to the patients by reducing the need for 
further unnecessary and potentially invasive investigations and 
will also lead to cost savings by reducing inappropriate onward 
referral of older patients without advanced liver disease to sec-
ondary care. A proposed algorithm for the use of the NFS and 
FIB-4 score that takes account of patient age is shown in  Figure 
4a,b . It is important to note that even with these new cutoff s the 
PPV for advanced fi brosis with the FIB-4 score and NFS was rel-
atively low if used in cohorts with a low prevalence of advanced 
fi brosis. Th erefore, patients with a raised score should undergo 
a second-line investigation to confi rm advanced fi brosis. Pre-
vious studies have shown that the major value of these simple 
non-invasive scores is to exclude rather than diagnose advanced 
fi brosis ( 19 ).
 Both the NFS and the FIB-4 score include age in their models 
and this might be one explanation for the reduction in speci-
fi city for advanced fi brosis with increasing age. However, we 
also demonstrated that the specifi city of the AST/ALT ratio 
for advanced fi brosis fell with increasing age. Th is was due to 
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 Figure 2 .  Relationship between serum alanine transaminase (ALT) level and age in patients with ( a ) stage F0–F1 fi brosis and ( b ) stage F2–F4 fi brosis. 
Relationship between serum aspartate aminotransferase (AST) level and age in patients with ( c ) stage F0–F1 fi brosis and ( d ) stage F2–F4 fi brosis. A full 
color version of this fi gure is available at the  American Journal of Gastroenterology journal online.
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and FIB-4 score include platelet count in their models, likely 
also contributing to the observed reduction in specifi city with 
increasing age.
 Another key fi nding of this study was that the AST/ALT ratio, 
NFS, and FIB-4 scores performed very poorly in patients aged <35 
years. In this age group, the AUROCs for advanced fi brosis for all 
three non-invasive scores did not reach statistical signifi cance, sug-
gesting that these scores are inaccurate and therefore should not be 
used to diagnose or exclude advanced fi brosis. Th e prevalence of 
advanced fi brosis was relatively low in this group compared with 
older patients, with 11% of subjects having stage F3 fi brosis and 
none being cirrhotic. Th e low prevalence of advanced fi brosis 
might be one explanation for the poor performance of these tests 
in this age group.
 In the United Kingdom, a recent Lancet Commission has set 
out a blueprint that aims to reduce premature mortality rates 
from liver disease and a key aspect of this is early recognition 
of patients with progressive and advanced liver disease in the 
community ( 22 ). One of the recommendations of this report is 
that all liver function test requests in the community should have 
both ALT and AST measured and the AST/ALT ratio should be 
displayed on the laboratory report. AST/ALT ratios >1 are to 
be fl agged to clinicians to recommend further liver assessment. 
Despite having looked very promising in some previous stud-
ies, the AST/ALT ratio performed relatively poorly in the present 
study with an overall AUROC of 0.70 for a diagnosis of advanced 
fi brosis ( 15,19 ). Results of the present study and others suggest 
that it might be more benefi cial to use the FIB-4 score or NFS 
as an alternative to the AST/ALT ratio as these appear more 
accurate ( 18,37,38 ). Although these are more complex to calcu-
late, the FIB-4 score only requires the addition of the age and 
platelet count to the AST and ALT and a simple online calculator 
is available ( http://gihep.com/calculators/hepatology/fi brosis-
4-score/ ).
 It is salutatory to note that, as with the FIB-4 and NFS, many 
of the other non-invasive tests for fi brosis that are used in clinical 
practice have not been validated for use in older-age cohorts, par-
ticularly when NASH and advanced fi brosis are seen more com-
monly on biopsy in older patients ( 39 ). Complex fi brosis panels 
that include markers of matrix turnover, such as the Enhanced 
Liver fi brosis panel and FibroTest, have shown promise for the 
assessment of liver fi brosis in NAFLD ( 40,41 ). However, these 
panels have been primarily developed in young and middle-aged 
patients with few patients aged ≥65 years studied. Th e Enhanced 
Liver fi brosis test may be less susceptible to an age-related bias as 
it does not include age in its mathematical model; however, there 
is published evidence that the test exhibits reduced diagnostic 
accuracy when age is >45 years and so clarifi cation of this point 
is needed ( 42 ). Further evaluation in older patients is clearly war-
ranted before accuracy can be assumed in older patients. Another 
commonly adopted method for non-invasive assessment of fi bro-
sis is liver stiff ness measurement assessed by transient elastogra-
phy. Th is technique is generally eff ective at excluding advanced 
fi brosis when reliable readings can be obtained and may perform 
better than simple non-invasive fi brosis tests ( 43 ). However, large 
studies have demonstrated that an insuffi  cient number of valid 
measurements may be achieved in some patients owing to adi-
posity and body habitus. Indeed, even when using the Fibroscan 
XL probe, which is adapted for obese patients, a valid result may 
not be achieved in up to 26% of subjects ( 44 ). In large-scale retro-
spective studies, older age (>52 years), along with central obesity 
and Type 2 diabetes mellitus, were the key independent factors 
predictive of failure to achieve valid liver stiff ness measurement 
( 45 ). Th ere is also recent evidence from an epidemidemiologi-
cal study that liver stiff ness may rise with age ( 46 ), suggesting 
that this test too may have reduced utility in older patients with 
NAFLD.
 Age-related changes in liver morphology may also contrib-
ute to the eff ect of increasing age on the performance of non-
invasive fi brosis tests, including elastography. Liver blood fl ow 
and liver mass are known to be reduced in the ageing liver ( 47 ). 
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 Figure 3 .  Plots of sensitivity and specifi city against age for new diagnostic 
cutoffs for advanced fi brosis for: ( a ) fi brosis 4 (FIB-4) score (2.0); 
( b ) non-alcoholic fatty liver disease fi brosis score (NFS) (0.12). Age range 
for which proposed thresholds are optimized is highlighted by red box. 
These show better specifi city than current cutoffs without an adverse 
effect on sensitivity. A full color version of this fi gure is available at the 
 American Journal of Gastroenterology journal online.
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prevalence. To counter this concern, as prevalence can vary in dif-
ferent populations, we have displayed PPVs and NPVs at diff er-
ent prevalence rates for the new derived cutoff s to aid clinicians 
using these scores in diff erent clinical settings. Finally, histologi-
cal assessment of liver fi brosis is an imperfect gold standard that 
is subject to both the eff ect of non-uniform distribution of histo-
logical lesions throughout the liver parenchyma and ascertainment 
variation ( 50–52 ). Liver biopsies were analyzed by a local patholo-
gist at each of the centers. Although all the pathologists reading the 
biopsies are highly experienced hepatopathologists, there is poten-
tial for interobserver variability, which may have led to a lowering 
of the diagnostic accuracy of the tests. Despite these limitations, the 
overall diagnostic accuracy of the non-invasive scores assessed in 
the present study are in keeping with other studies and this is the 
fi rst study to specifi cally assess these scores in specifi c age groups 
( 17,18,20,30–32 ).
 In conclusion, this study shows that age has a signifi cant eff ect 
on the performance of simple non-invasive fi brosis scores in diag-
nosing advanced fi brosis. Th e AST/ALT ratio, FIB-4 score, and 
NFS performed poorly in patients aged <35 years, suggesting that 
clinicians should use alternative means of non-invasive diagnosis 
It is also recognized that vascular morphology is modifi ed with 
increasing age with even healthy liver exhibiting defenestration 
of sinusoidal endothelial cells, sinusoidal fi brosis, increased 
hepatic arteriolar wall thickness, and decreased arteriolar 
diameter that may impair oxygen-dependent hepatocyte func-
tion ( 48,49 ).
 Th is study does have some limitations. First, the sample size of 
younger (≤35 years) and older patients (≥65 years) is relatively small 
despite a large overall cohort size, refl ecting that these patients are 
less likely to have a liver biopsy performed in routine clinical prac-
tice. Second, patients are likely to be highly selected, particularly 
the older patients (≥65 years), as clinicians tend to be reluctant to 
perform liver biopsy in older patients for fear of complications, 
unless they believe it is going to signifi cantly change the patient’s 
management. In addition, the prevalence of Type 2 diabetes was 
high (38%) in the young (<35 years) patients, which suggests selec-
tion bias as this rate of diabetes is higher than would be expected 
in a young cohort of patients with NAFLD. Th ird, the prevalence 
of advanced fi brosis was high in this study, again probably refl ect-
ing the selection bias, and this will have impacted on the PPVs and 
NPVs that have been displayed as they are heavily infl uenced by 
 Table 4 .  Performance of current and proposed new cutoffs to exclude advanced fi brosis (stage F3–F4) in older patients (≥65 years) at 
different prevalence rates of advanced fi brosis 
 Test  Cutoff  Sens. (%)  Spec. (%)  Prev. (%)  PPV (%)  NPV (%)  LR +ve  LR −ve 
 FIB-4  1.3  93  35  5  7  99  1.43  0.2 
     10  14  98   
     20  26  95   
     30  38  92   
     40  49  88   
  2.0  77  70  5  12  98  2.56  0.33 
     10  22  96   
     20  39  92   
     30  52  88   
     40  63  82   
 NFS  −1.455  93  20  5  6  98  1.16  0.35 
     10  11  96   
     20  23  92   
     30  33  87   
     40  44  81   
  0.12  80  70  5  12  99  2.67  0.29 
     10  23  97   
     20  40  93   
     30  53  89   
     40  64  84   
 FIB-4, fi brosis 4; LR +ve, positive likelihood ratio, LR −ve, negative likelihood ratio; NFS, non-alcoholic fatty liver disease fi brosis score; NPV, negative predictive value; 
Prev., prevalence; PPV, positive predictive value; Sens., sensitivity; Spec., specifi city. 
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of fi brosis in this age group. Th e overall diagnostic accuracy for 
advanced fi brosis using the NFS and FIB-4 score was acceptable 
in patients aged >35 years, but there was a signifi cant fall in speci-
fi city for advanced fi brosis in older patients (≥65 years), result-
ing in a high false positive rate for advanced fi brosis. To rectify 
this, while the existing thresholds should continue to be used 
in patients aged 35–65 years, we propose new cutoff s that will 
signifi cantly improve the accuracy of the NFS and FIB-4 score in 
patients aged ≥65 years.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE? 
 ✓  Simple non-invasive fi brosis scores, such as the NAFLD 
fi brosis score, FIB-4 score, and AST/ALT ratio, are widely 
used to exclude advanced fi brosis in patients with NAFLD. 
 ✓  These non-invasive scores have not been evaluated in 
patients at the extremes of age (<35 years or >65 years). 
 WHAT IS NEW HERE? 
 ✓  The NAFLD fi brosis score, FIB-4 score, and AST/ALT ratio 
perform poorly in patients aged <35 years. 
 ✓  The NAFLD fi brosis score and FIB-4 have low specifi city 
for advanced fi brosis in patients aged >65 years leading to 
a high false positive rate. 
 ✓  New cutoffs for excluding advanced fi brosis for patients 
aged >65 years have been derived (and validated) for the 
NAFLD fi brosis score and FIB-4 score, which reduced the 
false positive rate without adversely affecting sensitivity. 
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